Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...
Despite recent market turbulence, Oppenheimer Asset Management expressed continued optimism about equities in a statement ...
As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...
Oppenheimer raised the firm’s price target on AT&T to $32 from $27 and keeps an Outperform rating on the shares. The firm cites better free ...
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Biomea Fusion (BMEA – Research Report), with a price ...
Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...
Oppenheimer maintained its Outperform rating on AppLovin (APP) while highlighting key points for the company from the ...
Yet, MAD still dominates countries’ nuclear thinking. Opinion: Our nuclear weapons are much more powerful than Oppenheimer's atomic bomb At a time of profound global changes and instability ...
Joshua Oppenheimer made his name directing two disturbing documentaries, The Act of Killing (2012) and The Look of Silence ...
Oppenheimer analysts initiated coverage on Cloudflare (NYSE:NET) with an Outperform rating and Fastly (NYSE:FSLY) with a Perform rating in separate notes Thursday.
Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had one of the most incredibly stacked casts in recent memory. Jack Quaid ...